Edesa Biotech Inc Quick Ratio (EDSA) starting from the third quarter 2026 to third quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Edesa Biotech Inc   (NASDAQ: EDSA)

Edesa Biotech Inc 's Quick Ratio

EDSA's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 2.63 below Edesa Biotech Inc average.

Within Major Pharmaceutical Preparations industry 254 other companies have achieved higher Quick Ratio than Edesa Biotech Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 743 to 1211.

Explain Quick Ratio?
How much Cash & cash equivalents EDSA´s has?
What are EDSA´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/EDSA/financial-strength
https://api.csimarket.com/api/v1/companies/EDSA/fundamentals
https://api.csimarket.com/api/v1/companies/EDSA/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
EDSA Quick Ratio (Jun 30 2026)
Q3		 (Mar 31 2026)
Q2 		(Dec 31 2025)
Q1 		(Sep 30 2025)
Q4 		(Jun 30 2025)
Q3
Y / Y Current Liabilities Change 481.25 %
Y / Y Cash & cash equivalent Change -16.94 %
Quick Ratio MRQ 2.63
EDSA's Total Ranking # 1211
Seq. Current Liabilities Change 78.71 %
Seq. Cash & cash equivalent Change 3 %



Quick Ratio third quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 255
Healthcare Sector # 436
Overall Market # 1211


Quick Ratio Statistics
High Average Low
39.75 11.45 0.55
(Dec 31 2018)   (Dec 31 2024)




Financial Statements
Edesa Biotech Inc 's Current Liabilities $ 4 Millions Visit EDSA's Balance sheet
Edesa Biotech Inc 's Cash & cash equivalent $ 10 Millions Visit EDSA's Balance sheet
Source of EDSA's Sales Visit EDSA's Sales by Geography


Cumulative Edesa Biotech Inc 's Quick Ratio

EDSA's Quick Ratio for the trailling 12 Months

EDSA Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months 		(Dec 31 2025)
12 Months 		(Sep 30 2025)
12 Months 		(Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 49.66 %
Y / Y Cash & cash equivalent TTM Growth 49.48 %
Quick Ratio TTM 5.45
Total Ranking TTM # 3559
Seq. Current Liabilities TTM Growth 68.95 %
Seq. Cash & cash equivalent TTM Growth -4.64 %

Quick ratio ranking by company, industry and sector >> Back to EDSA Financial Strength Comparisons >> Go to Compare EDSA Quick Ratio to its Competitors

On the trailing twelve months basis Due to jump in Current Liabilities in the Q3 2026 to $3.91 millions, cumulative Quick Ratio decreased to 5.45 above the EDSA average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 421 other companies have achieved higher Quick Ratio than Edesa Biotech Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 3291 to 3559.

Explain Quick Ratio?
How much Cash & cash equivalents EDSA´s has?
What are EDSA´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 422
Healthcare Sector # 859
Within the Market # 3559


trailing twelve months Quick Ratio Statistics
High Average Low
12.79 5.21 0.24
(Dec 31 2025)   (Dec 31 2024)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Aspire Biopharma Holdings Inc   7.22 $ 12.167  Millions$ 1.686  Millions
Cartesian Therapeutics Inc   7.18 $ 147.606  Millions$ 20.550  Millions
Mereo Biopharma Group Plc  7.17 $ 30.506  Millions$ 4.256  Millions
Kiora Pharmaceuticals Inc   7.10 $ 16.839  Millions$ 2.370  Millions
Arvinas Inc   6.88 $ 567.900  Millions$ 82.500  Millions
Alumis inc   6.59 $ 502.300  Millions$ 76.233  Millions
Novelos Therapeutics, Inc.  6.49 $ 33.994  Millions$ 5.238  Millions
Genprex Inc   6.47 $ 15.154  Millions$ 2.342  Millions
Lisata Therapeutics Inc   6.45 $ 19.277  Millions$ 2.987  Millions
Larimar Therapeutics Inc   6.44 $ 219.880  Millions$ 34.166  Millions
United Therapeutics Corporation  6.13 $ 3,724.700  Millions$ 607.800  Millions
Serina Therapeutics Inc   6.12 $ 23.024  Millions$ 3.762  Millions
Revelation Biosciences Inc   6.11 $ 11.483  Millions$ 1.880  Millions
Spero Therapeutics Inc   6.02 $ 50.774  Millions$ 8.428  Millions
Aquestive Therapeutics Inc   5.98 $ 98.490  Millions$ 16.478  Millions
Xencor Inc  5.94 $ 486.350  Millions$ 81.865  Millions
Zymeworks Inc   5.73 $ 270.699  Millions$ 47.243  Millions
Tonix Pharmaceuticals Holding Corp   5.72 $ 176.232  Millions$ 30.785  Millions
Emmis Acquisition Corp   5.72 $ 0.708  Millions$ 0.124  Millions
Arcturus Therapeutics Holdings Inc   5.71 $ 191.483  Millions$ 33.536  Millions
Hoth Therapeutics Inc   5.70 $ 7.892  Millions$ 1.384  Millions
Silence Therapeutics Plc  5.67 $ 72.054  Millions$ 12.714  Millions
Adial Pharmaceuticals Inc   5.51 $ 28.200  Millions$ 5.121  Millions
Corbus Pharmaceuticals Holdings Inc   5.49 $ 117.941  Millions$ 21.483  Millions
Bio Green Med Solution Inc   5.48 $ 3.790  Millions$ 0.692  Millions
Arrowhead Pharmaceuticals Inc   5.47 $ 1,551.301  Millions$ 283.346  Millions
Context Therapeutics Inc   5.45 $ 42.990  Millions$ 7.885  Millions
Annexon Inc   5.44 $ 209.200  Millions$ 38.482  Millions
Arbutus Biopharma Corp  5.35 $ 19.172  Millions$ 3.585  Millions
Cns Pharmaceuticals Inc   5.35 $ 19.985  Millions$ 3.738  Millions

Date modified: 2026-10-05T11:03:41+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.